For pharma IP teams, R&D leads, CROs, and portfolio managers who need more than a surface-level overview. Why Pharmacists Are […]
The blueprint for drug competition is clean on paper. A company wins a 20-year patent, recovers its R&D investment during
Off-Patent, Zero Competition: Why Some Off-Patent Drugs Have No Generic Rivals Read Post »
I. The Core Problem: Effective Patent Life vs. Nominal Term The pharmaceutical business runs on a single structural tension: the
How Pharma Reads Patent Filings to Predict Post-Expiration Revenue — And Defend It Read Post »
1. Why the NCE-Only Mental Model Is Costing You IP Value Key Takeaways The phrase ‘patent cliff’ has been overused
Why Effective Patent Life Is the Only Number That Matters Every pharmaceutical deal, licensing negotiation, and portfolio valuation ultimately hinges
1. Why API Supplier Selection Is an IP and Valuation Decision, Not a Procurement Function Most pharmaceutical procurement teams still
Section 1: What Freedom to Operate Actually Means — and What It Does Not 1.1 The Core Definition Freedom to
The $300 Billion Map: Why the Patent Cliff Is Your Best Market Signal {#market-signal} A drug patent is two things
Section 1: The Strategic Foundations of Pharmaceutical Pricing The price of a new drug is not calculated. It is constructed.
Get fresh news and insights, drug patent expirations & more…
